
Abla Creasey



Abla Creasey

Senior Director of Strategic Clinical, Regulatory, and Infrastructure Programs

Abla oversees CIRM's Strategic Infrastructure (the Alpha Clinics Network, the Accelerating Center and Translating Center and CIRM's basic research infrastructure-genomics and iPSC programs) and CIRM's Clinical Advisory Panel. Previously at CIRM, Dr. Creasey helped the Therapeutics Team achieve the bold goal of bringing in 10 new clinical trials in Year 1 of CIRM's 5-year strategic plan. She has exemplified the "All In" attitude that drives success for the team and for CIRM towards its mission of accelerating stem cell treatment to patients with unmet medical needs.

Abla has broad and extensive experience in science, technology, and pharmaceutical product development. Prior to joining CIRM in 2016, she was at Johnson & Johnson for 12 years. While at Johnson and Johnson, Abla was a Senior Scientific Director in Pharmaceutical Development & Manufacturing Sciences at Janssen and prior to that, she was, an Executive Director, heading drug delivery, pharmacology, analytical characterization, clinical & quality at Advanced Technologies & Regenerative Medicine (ATRM), another J&J company. Prior to ATRM, Abla was Vice President of Biological Sciences at ALZA Corporation, where she headed discovery efforts in formulation, preclinical and oral drug delivery. Before joining ALZA in 2004, Abla held senior-level positions in R&D, clinical development, and regulatory affairs within the biotechnology industry including Chiron Corporation and Cetus Corporation.

Abla received a B.S. in biology from the College of Notre Dame in Belmont California, and earned her Ph.D. in medical microbiology from the University of California, Berkeley. She completed a post-doctoral fellowship at the Stanford University School of Medicine in infectious disease, biochemistry, and immunology.

Source URL: <https://www.cirm.ca.gov/leadership/abla-creasey>